The Phase 2 results of the recombinant Kovid-19 vaccine candidate, adjuvants of Sanofi and GSK, have been announced. Accordingly, according to the results of the Phase 2 study in which 722 volunteers participated, strong neutralizing antibody responses were observed in the measured rates of the vaccine candidate surviving the Kovid-19 disease in all adult age groups participating in the study. According to the Phase 2 interim results, Sanofi and GSK’s second dose of the Kovid-19…"Phase 2 results of Kovid-19 vaccine candidates have been announced"
08 May 2021 Saturday – 15:48 | Last Updated: 08 05 2021 – 15:48 Turkey Health Institutes Presidency Biotechnology Institute Vaccine Scientific Committee Member Prof. Dr. Tarlan Mammedov announced that they have developed 2 coronavirus vaccine candidates, 1 drug and 3 kits produced from plant leaves at Akdeniz University (AU). Prof. Dr. Stating that they have achieved good results in human trials, Mammedov said that they expect support from vaccine companies. AÜ Faculty of Agriculture,…"They are waiting for support for 2 vaccine candidates, 3 kits and 1 drug"
TUBITAK 19 Turkey Platform Covidien-time work under the roof and most innovative vaccines based on one of the accepted methods of virus-like particles (VLP) became the 4th vaccine candidate in the world to switch to human trials of the vaccine study, and the World Health Organization (DSÖ) made it to the list. According to the statement made by the Ministry of Industry and Technology, Covid-19 The relevant organizations before entering the territory of Turkey Ministry…"Turkey’s innovative vaccine candidates entered the WHO list – Health News"